双表位靶向实现1型与2型CALR突变MPN的超精准治疗并恢复芦可替尼敏感性
该研究针对CALR第1型(del52)与第2型(ins5)突变骨髓纤维化,采用两种识别不同表位的单克隆抗体双靶向治疗。双靶向在体外和人源化骨小梁微环境中清除原代巨核祖细胞优于单药,并克服芦可替尼耐药;第2型突变对 antibody 靶向部分抵抗,但可被芦可替尼三联方案影响。
要点
- 双表位抗体靶向del52 CALR可增强清除巨核祖细胞并改善异种移植模型生存。
- 双靶向阻断STAT5与ERK磷酸化并阻止JAK2磷酸化积累,克服芦可替尼耐药。
- 第2型CALR突变二聚化增强、对抗体部分抵抗,需芦可替尼三联方案。
核心结论
- 针对1型与2型CALR突变需采用超精准分型治疗策略以最大程度阻断JAK/STAT信号。
研究设计与样本
- 研究采用两种针对CALR不同表位的单克隆抗体进行双靶向,在体外原代巨核祖细胞、人源化骨小梁微环境和异种移植模型中评价疗效。
主要发现
- 双靶向del52 CALR在清除原代巨核祖细胞和改善异种移植模型生存方面优于单药治疗。
- 双靶向阻断del52诱导的STAT5和ERK磷酸化,并阻止JAK2磷酸化积累,克服芦可替尼耐药。
- 2型突变显示CALR二聚化增加,对抗体靶向部分抵抗,但可受芦可替尼三联组合影响。
临床怎么用
- 对CALR突变MPN应按1型与2型分类选择精准靶向策略,1型可考虑双表位抗体,2型需联合芦可替尼。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Somatic frameshift mutations in the gene encoding calreticulin (CALR) give rise to myelofibrosis and are classified as type 1 (del52) or type 2 (ins5) according to the degree of wild-type sequence retained adjacent to the neopeptide, with each type conferring different clinical outcomes. Targeting strategies specific for type 1 vs type 2 mutations would have enormous clinical utility in the treatment and prevention of myelofibrosis as responses to tyrosine kinase inhibitors are not durable nor mutation specific. Here, we show that dual targeting of type 1 (del52) mutant CALR with 2 monoclonal antibodies directed against distinct epitopes in CALR have significant advantages compared with single-agent treatment in the eradication of primary megakaryocyte progenitors in vitro and in a humanized ossicle microenvironment leading to improved survival in xenograft models. Dual targeting was superior in blocking constitutive STAT5 and extracellular signal-regulated kinase phosphorylation induced by del52 and prevented accumulation of Janus kinase 2 (JAK2) phosphorylation, overcoming ruxolitinib resistance. In contrast, type 2 mutations showed increased CALR dimerization and were partially resistant to antibody targeting but could be affected by a ruxolitinib triple combination. Together, our data demonstrate an ultraprecision medicine approach tailored to either type 1 or type 2 mutation classes will be required for maximal efficacy and complete blockade of JAK/STAT signaling, with far-reaching implications for patient management.
引用
- Thompson-Peach CAL, Thomas D, Dottore M, et al. Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity. Blood. 2026. PMID: 41481383. doi:10.1182/blood.2024027897
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。